URO-TECH CHALLENGE, THE HACKATHON DEDICATED TO UROLOGY
Pierre Fabre organized its first Hackathon dedicated to urology at the Health Communication Festival in November 2016. This first edition brought together nearly 40 expert developers, designers, marketers, IT services companies, start-ups, specialist physicians and patients who put forward nine innovative projects for patients and health care professionals.
The “Uro-Tech Challenge” hackathon focused on exploring e-health solutions for patients with overactive bladder (OAB). This neglected disease affects 55 million people in Europe, of whom only nine million are receiving medical treatment (16%).
The winning projects will benefit from a two-month incubation by Pierre Fabre, accompanied by BeMyApp, an expert in the development of joint creative projects. This incubation will enable the three selected teams to transform their idea into a potentially operational reality and launch a start-up of their own.
PIQUR AND PIERRE FABRE SIGN A PARTNERSHIP AGREEMENT IN THE AREA OF DERMATO-ONCOLOGY
PIQUR Therapeutics AG, a Swiss company specialized in the development of pharmaceutical products in clinical phase, and Pierre Fabre have announced the signing of the collaboration agreement to assess and develop formulations for the PI3K/mTOR inhibitors for various therapeutic indications.
POSITIVE RESULTS OF THE PHASE 3 COLUMBUS STUDY IN MELANOMA
Pierre Fabre announced the first results of the pivotal phase 3 COLUMBUS trial with the treatment combining binimetinib and encorafenib (bini/enco) in BRAF-mutant melanoma patients. The study has achieved its primary endpoint, with the bini/enco combination significantly improving progression-free survival (PFS) compared with vemurafenib, a BRAF inhibitor, on its own. The bini/enco combination was well tolerated on the whole, and the reported adverse events were overall consistent with previously published clinical trial results on the bini/enco combination in BRAF-mutant melanoma patients.
The Toulouse Cancer Health Foundation and the Pierre Fabre Research Institute are creating a research Chair in immuno-oncology
The Pierre Fabre Research Institute and the Toulouse Cancer Health Foundation announced the joint creation of a research Chair dedicated to immune-oncology research. This Chair, with equal funding given for five years by the Toulouse Cancer Health Foundation and the Pierre Fabre Research Institute, will be part of the Cancer Research Center of Toulouse (CRCT) at the Oncopole in Toulouse.
SIGNING OF THE 1st PARTNERSHIP AGREEMENT WITH NATURE OPEN LIBRARY
In February 2016, Pierre Fabre Laboratories and Plasticell signed a partnership agreement to identify the natural stimulants of the brown adipose tissue for the treatment and prevention of obesity and diabetes.
PIERRE FABRE ORAL CARE AND THE UNION FRANÇAISE POUR LA SANTÉ BUCCO-DENTAIRE ORGANIZE THE “SMILING SPRING”
Aware of the position of oral care at the heart of global health and of the importance of helping all French people acquire proper daily oral care reflexes, Pierre Fabre Oral Care, a key player in pharmacy, and the Union Française pour la Santé Bucco-Dentaire have come up with a season dedicated to awareness, motivation and education with the “Smiling spring”: a set of actions to adopt “Good Resolutions” for our oral care!
“J’AIME MON DENTISTE” (I LOVE MY DENTIST): AN ORIGINAL OPERATION BY PIERRE FABRE ORAL CARE
More than half of French people are anxious about oral care. Stressed, anxious, frightened … these are the words that 84% of French people use to describe their state of mind when going to or during a dentist appointment.
With “I love my dentist,” Pierre Fabre Oral Care has developed national communication and training initiatives to help anxious patients, and dental surgeons as well, to make them aware of the right thing to say and do to reassure their stressed patients.
To take this awareness to the next level, dental surgeons will have access to a VIRTUAL COACH in the form of e-learning to learn about the stress that may be felt by their patients.
PIERRE FABRE PHARMACEUTICALS LAUNCHES FEELCAPS TO RAISE PATIENTS’ AWARENESS OF THE BENEFITS OF REGULAR PHYSICAL EXERCISE
Launch of a new digital health service named “FeelCaps” intended for chronic patients, which will be offered for free by their doctor.
As a game, Feelcaps is an educational, adaptable and easy-to-use online platform, which will help patients to better understand the importance of regular exercise for their health. Patients will find it easier to get motivated for one or more APAs suited to their chronic pathology.
open innovation: DayONE!
The “DAY ONE” forum, organized jointly by the Pierre Fabre Research Institute and the Cancer-Bio-Health Competitiveness Cluster, brought together more than 300 innovators in oncology, dermatology and onco-dermatology at the Oncopole site in Toulouse.
More than 30 start-ups from different cities in the Greater South-Western region (Nantes, Bordeaux, Limoges, Toulouse, Montpellier) presented their projects in the form of pitches to an extremely varied audience, such as Research and Development teams, academics (INSERM, CNRS), members of the Toulouse Cancer Research Center (CRCT) and the Cancer University Institute of Toulouse (IUCT), as well as organizations seeking to fund innovative projects (Capitole Angels, BPI, and Pierre Fabre Fund for Innovation, among others).
LAUNCH OF A JOINT PROJECT IN TRANSLATIONAL MEDICINE
Pierre Fabre Pharmaceuticals announces the organization of a research project in translational medicine on a drug candidate produced by its pharmaceutical research in oncology. A collaboration will be set up between Professor David Rimm MD-PhD, Professor of Pathology at the Yale University Medical School, and the department dedicated to translational medicine and headed by Dr. Alexandre Passioukov within Pierre Fabre Pharmaceuticals R&D.
POSITIVE RESULTS OF A CLINICAL TEST IN SCHIZOPHRENIA
F17464 is a preferential dopamine D3 receptor antagonist from Pierre Fabre Research in the Central Nervous System, which presents an original mode of action. The initial pharmacology and safety results being very encouraging, F17464 was subjected to a clinical trial program, including the FAST study, designed to assess the efficiency and safety of F17464 in relation to the placebo in schizophrenic patients presenting an acute episode.
LAUNCH OF PIERRE FABRE FUND FOR INNOVATION
The Group is launching an original open innovation initiative, Pierre Fabre Fund for Innovation, for biotech companies, start-ups and public and private research laboratories specializing in oncology or dermatology, as a priority in France and Europe.
The research projects supported by Pierre Fabre Fund for Innovation are either less than 24 months from the transition from the pre-clinical phase to clinical development (Phase 1) or in the early phases of clinical development. This fund offers various types of collaboration, which may be combined: provision of Pierre Fabre Pharmaceuticals skills, co-funding for the research program, a minority stake in the capital or license agreement.